Latest Sustainable Growth News

Volt Resources has completed a scoping study for its Alabama Graphite Refinery, revealing robust project economics and a patented purification process that could reshape US graphite supply chains.

Bathurst Resources reports robust cash reserves and steady profitability while progressing development of its Buller and Tenas metallurgical coal projects. The company also navigates ongoing litigation that could impact its governance.

The Calmer Co. has secured a major retail milestone by launching its Fiji Kava 50g Instant Kava product across Woolworths supermarkets nationwide, significantly broadening its Australian footprint.

Unico Silver Limited has reported its highest silver intercept to date at the Cerro Leon project, delivering significant near-surface and deeper mineralisation that underpins its dual-track growth strategy.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.

Minbos Resources reports strong 2024-25 field trial results for its phosphate fertilizer PRIMEIRO™ in Angola, while expanding its product range with PRIMEIRO PLUS+, a blended NPKS solution tailored to local soils and crops.

Control Bionics is on track for its strongest financial year yet, driven by robust US and Australian sales and promising global trials of its NeuroStrip® device.

NexGen Energy has secured regulatory approval for a significant infrastructure upgrade at its Rook I uranium project, setting the stage for expanded exploration and operational efficiency in 2025.

Challenger Limited has welcomed APRA’s consultation on new capital settings for annuity products, highlighting the potential for regulatory reforms to boost innovation and growth in Australia’s retirement income sector.

AnteoTech secures a significant purchase order from the Serum Institute of India, driving its Life Sciences unit toward a projected 130% sales increase in FY2025 despite some project delays.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.

Clover Corporation has upgraded its FY25 earnings forecast, expecting net profit after tax to exceed market consensus by around 20%, driven by strong sales and operational improvements.